HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design

Ángel Bayón-Gil1, Maria C Puertas1, Víctor Urrea1

  • 1IrsiCaixa AIDS Research Institute, Badalona, Spain.

Abstract

Insights

Early combination antiretroviral therapy (cART) for HIV-1 infection leads to viral reservoir stabilization after two years. This finding is crucial for designing effective viral remission strategies and interpreting clinical trial outcomes in HIV-1 management.

Area of Science:

  • Virology
  • Immunology
  • Infectious Diseases

Background:

  • Early initiation of combination antiretroviral therapy (cART) for HIV-1 infection is key to limiting viral reservoir establishment.
  • Understanding HIV-1 DNA decay dynamics in early-treated individuals is essential for developing novel viral remission strategies.
  • Poorly defined decay dynamics can hinder the design and interpretation of clinical trials targeting HIV-1 reservoirs.

Purpose of the Study:

  • To determine the necessary duration of cART for stabilizing the HIV-1 reservoir in individuals treated early after infection.
  • To clarify the kinetics of HIV-1 DNA decay under cART in a cohort of early-treated patients.

Main Methods:

  • Longitudinal analysis of total HIV-1 DNA levels using droplet digital PCR in 21 individuals initiating cART within 6 months of infection.
  • Measurements were collected at cART initiation, 6 months, and annually up to Year 4.
  • Statistical modeling, including mixed-effects models, was used to analyze correlations between virological and clinical parameters.

Main Results:

  • Total HIV-1 DNA showed a median decrease of 1.43 log10 units over 4 years of follow-up.
  • Baseline HIV-1 DNA, viral load, CD4+ T cell count, and CD4+/CD8+ ratio significantly correlated with final HIV-1 DNA levels.
  • Statistical modeling indicated that the viral reservoir reached a stable set point after 2 years on cART.

Conclusions:

  • A 2-year treatment period with cART should be considered when designing interventions aimed at reducing latent HIV-1 reservoirs.
  • This waiting period is important for interpreting results from studies on viral rebound kinetics after cART discontinuation.
  • Considering this stabilization period enhances the potential for achieving sustained viral control in HIV-1 remission strategies.